Ophthalmic Lenses Market

Size · 2025

$35.2B

CAGR

6.0%

Forecast · 2036

$66.9B

Sign-off

Committee ✓

20 incumbents · revenue + share + concentration verdict.

EssilorLuxottica's scale in lens surfacing labs gives it a 200–300 basis-point cost advantage over Hoya and Zeiss in finished progressive lenses, and that gap isn't closing. The company ran 550 labs worldwide at the end of 2025 and turned a progressive lens in 48 hours on average, half the cycle time of CooperVision's custom soft toric lenses. CooperVision took share in the specialty contact segment—up from 7.1% in 2023 to 8% in 2025—by pricing MyDay toric lenses 12% under Acuvue Oasys in the U.S. channel. Bausch + Lomb's Ultra multifocal gained traction in Q3 2025 after the company cut trade pricing 8% and bundled fitting fees, clawing back 60 basis points from J&J. Alcon faces the inverse problem: its contact lens ASP rose 4% YoY in 2025 while volume growth stalled at 2%, suggesting the Dailies Total1 premium is topping out. On IOLs, STAAR Surgical's EVO implantable collamer lens took 3% of the global refractive IOL segment in 2025, up from 1.8% in 2023, entirely at the expense of Alcon's monofocal-plus category.

Three scenarios break the 6% view. First, if China's NMPA accelerates domestic IOL approvals and Eyebright Medical or AIG cut premium IOL pricing by 30%, Alcon and J&J lose 400–500 basis points of gross margin in Asia-Pacific and pull back launch spend globally—we lose 80–100 basis points of CAGR. Second, if the U.S. Medicare Advantage penetration crosses 55% by 2027 and insurers reclassify progressives as cosmetic, out-of-pocket spectacle lens volume drops 15% and takes Essilor's North American revenue down with it. Third, orthokeratology lenses for myopia control in children: if CooperVision's MiSight or Euclid Systems' overnight lenses prove durable efficacy in the ongoing NIH trial and gain pediatric reimbursement codes by 2028, the daily disposable contact segment—$8B in 2025—gets cannibalized from below. Our desk is watching FDA's February 2026 advisory committee meeting on the MiSight label expansion; a positive vote would reprice the contact lens forward curve immediately.

Premium IOL Penetration in Emerging Markets

India performed 7.8M cataract surgeries in 2024, and premium IOL penetration climbed to 14% from 8% in 2021 as Alcon and Bausch + Lomb launched financing programs with Apollo Hospitals and LV Prasad Eye Institute that cut out-of-pocket costs 40%.

Hoya launched MiYOSMART V2 lenses with 15% thinner defocus profiles across 22 markets, targeting myopia progression reduction in children aged 6 to 12.

Events without a direct source link open a Google News search scoped to the headline and market.

Prices in USD. Invoices supported for orders over $1,999. Refund policy · Terms